95 related articles for article (PubMed ID: 10948345)
1. Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.
Reinhold U; Ugurel S; Tilgen W; Kadiata MM; Olivares E; Nadi AB; Malaisse WJ
Oncol Rep; 2000; 7(5):1093-7. PubMed ID: 10948345
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Prignano F; Coronnello M; Pimpinelli N; Cappugi P; Mini E; Giannotti B
Cancer Lett; 2002 Dec; 186(2):183-92. PubMed ID: 12213288
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Schadendorf D; Worm M; Algermissen B; Kohlmus CM; Czarnetzki BM
Cancer; 1994 Jan; 73(1):103-8. PubMed ID: 7506115
[TBL] [Abstract][Full Text] [Related]
4. Methadone-Not a magic bullet in melanoma therapy.
Brüggen MC; Mangana J; Irmisch A; French LE; Levesque MP; Cheng PF; Dummer R
Exp Dermatol; 2018 Jun; 27(6):694-696. PubMed ID: 29577418
[TBL] [Abstract][Full Text] [Related]
5. Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.
Ingels A; Dinhof C; Garg AD; Maddau L; Masi M; Evidente A; Berger W; Dejaegher B; Mathieu V
Cancer Chemother Pharmacol; 2017 May; 79(5):971-983. PubMed ID: 28389780
[TBL] [Abstract][Full Text] [Related]
6. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
[TBL] [Abstract][Full Text] [Related]
8. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Chen M; Osman I; Orlow SJ
Mol Cancer Res; 2009 May; 7(5):703-12. PubMed ID: 19435820
[TBL] [Abstract][Full Text] [Related]
9. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
10. The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma.
Mohith A; Photiou A; Retsas S
Anticancer Drugs; 1996 Jun; 7(4):493-8. PubMed ID: 8826619
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons.
Schadendorf D; Jurgovsky K; Worm M; Czarnetzki BM
Melanoma Res; 1994 Aug; 4(4):243-9. PubMed ID: 7524835
[TBL] [Abstract][Full Text] [Related]
12. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Lartigau E; Guichard M
Br J Cancer; 1996 Jun; 73(12):1480-5. PubMed ID: 8664116
[TBL] [Abstract][Full Text] [Related]
13. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G
Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic action of 2-deoxy-D-glucose tetraacetate in tumoral pancreatic islet cells.
Malaisse WJ; Delvaux A; Rasschaert J; Kadiata MM
Cancer Lett; 1998 Mar; 125(1-2):45-9. PubMed ID: 9566695
[TBL] [Abstract][Full Text] [Related]
15. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine.
Merighi S; Mirandola P; Varani K; Gessi S; Capitani S; Leung E; Baraldi PG; Tabrizi MA; Borea PA
Biochem Pharmacol; 2003 Sep; 66(5):739-48. PubMed ID: 12948854
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
17. Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Ryabaya OO; Inshakov AN; Egorova AV; Emelyanova MA; Nasedkina TV; Zasedatelev AS; Khochenkov DA; Stepanova EV
Anticancer Drugs; 2017 Mar; 28(3):307-315. PubMed ID: 27941537
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by 2-deoxy-D-glucose tetraacetate of the cytostatic action of alpha-difluoromethylornithine in tumoral insulin-producing cells.
Olivares E; Malaisse WJ
Oncol Rep; 1998; 5(6):1395-7. PubMed ID: 9769375
[TBL] [Abstract][Full Text] [Related]
19. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
20. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
